
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Icad Inc | NASDAQ:ICAD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 4.37% | 2.39 | 2.31 | 2.39 | 2.36 | 2.21 | 2.27 | 188,359 | 22:44:35 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________________________
FORM
________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
________________________
(Exact Name of Registrant as Specified in Its Charter)
________________________
(State or Other Jurisdiction of Incorporation)
(Commission File Number) |
(IRS Employer Identification No.) | |
(Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered | ||
The |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. | Results of Operations and Financial Condition |
On January 27, 2025, iCAD, Inc. (the “Company”) issued a press release announcing certain preliminary, unaudited financial information, for the fourth quarter ended December 31, 2024, and other corporate updates. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 | Financial Statements and exhibit |
Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
(d) Exhibits
99.1 | Press Release of iCAD, Inc. dated January 27, 2025. |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
iCAD, INC. (Registrant) | ||
By: | /s/ Dana Brown | |
Dana Brown Chief Executive Officer and President |
Date: January 27, 2025
iCAD Pre-Announces Estimated Q4 2024 Revenue
iCAD to Participate in the BTIG at Snowbird:
12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
NASHUA, NH., January 28, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported select preliminary, unaudited financial results for the fourth quarter of 2024. Based on preliminary, unaudited financial information, the Company expects total revenue for the fourth quarter of 2024 to be between approximately $5.1 and approximately $5.3 million. Total Annual Recurring Revenue (T-ARR) was approximately $9.8 million, up 11% year-over-year. In the fourth quarter of 2024, the Company closed 106 deals, 19 of which were cloud deals with both new and established customers.
iCAD also announces it will participate in the BTIG at Snowbird: 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 11-12, 2025, in Snowbird, Utah. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD will participate in one-on-one meetings with investors at the event. To request a meeting with iCAD, investors should contact their BTIG representative.
iCAD’s consolidated financial statements for the twelve months ended December 31, 2024, are not yet available, and full audited results for the fourth quarter and year ended December 31, 2024 will be announced in March 2025.
The preliminary estimated financial information included in this press release for the fourth quarter ended December 31, 2024 is based solely on management’s estimates reflecting currently available preliminary information, and remains subject to iCAD’s consideration of subsequent events, particularly as it relates to material estimates and assumptions used in preparing our consolidated financial statements for the twelve months ended December 31, 2024. iCAD’s final consolidated financial results as of and for the three months ended December 31, 2024 may differ materially from estimates and the interim balances set forth in this release. Furthermore, the information presented herein does not include all information necessary for an understanding of the Company’s full fiscal year ended December 31, 2024.
Use of Non-GAAP Financial Measures
In its news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. When analyzing the Company’s operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP. The Company’s quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company’s website at www.icadmed.com
About iCAD
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. The ProFound Breast Health Suite is cleared by the U.S. Food & Drug Administration (FDA) and has received CE mark and Health Canada licensing. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, visit www.icadmed.com.
Forward-Looking
Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements about the Company’s financial results, expansion of access to the
Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of
the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements
involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements
of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking
statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the
willingness of patients to undergo mammography screening in light of risks of potential exposure to illnesses including Covid-19, whether
mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity
and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and
manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in
litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence
of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our
existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and
other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,”
“intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,”
“likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place
undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation
to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by
iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors
section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Media Inquiries:
pr@icadmed.com
Investor Inquiries:
ir@icadmed.com
Cover |
Jan. 27, 2025 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 27, 2025 |
Entity File Number | 001-09341 |
Entity Registrant Name | iCAD, INC. |
Entity Central Index Key | 0000749660 |
Entity Tax Identification Number | 02-0377419 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 98 Spit Brook Road, Suite 100 |
Entity Address, City or Town | Nashua |
Entity Address, State or Province | NH |
Entity Address, Postal Zip Code | 03062 |
City Area Code | (603) |
Local Phone Number | 882-5200 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.01 par value |
Trading Symbol | ICAD |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
1 Year Icad Chart |
1 Month Icad Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions